FDA MedWatch Alert issued on January 31, 2014
Some of the prescription testosterone drug products approved by the FDA and available for use to treat low testosterone, or “Low T” syndrome, include:
Testosterone replacement therapy (TRT) is also referred to as androgen replacement therapy (ART) and male hormone replacement therapy.
Unfortunately, while it is estimated that the number of middle-aged men in the U.S. getting testosterone treatment has more than tripled over the last decade, the long-term risks are largely unknown.
Men with certain cardiac conditions such as heart disease who are prescribed these testosterone replacement therapy medications face an increased risk of cardiovascular adverse events according to a medical study article, “Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels”, published in the November 6, 2013 edition of the Journal of American Medical Association.
To put this rather alerting drug safety information about testosterone replacement therapy into context we look to a November 2013 medical news report,“‘Low T’ Tx Tied to Higher Stroke Risk in Veterans”:
Steven Nissen, MD, of the Cleveland Clinic, characterized the study results as a red flag that demands “attention not just from physicians but also from regulators.”
We will continue to report about testosterone therapy and its increased risk of death, heart attacks, and strokes — as well as how these “Low T” drugs like Axiron, AndroGel, and Testim became so popular — in our next article about this emerging drug safety issue.
If you or someone you know has suffered a heart condition injury due to testosterone replacement therapy, contact Guldjian immediately for a free consultation at 800-385-4835.